000			04451nam a22004575i 4500
999			_c121994 _d121994 _x1
001			121994
003			ES-MaUEC
005			20230102114157.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			200731s2020 gw a o |||| 0|eng d
020			_a9783030494766
024	7		_a10.1007/978-3-030-49476-6 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280.P25 _b2020 EB
245	0	0	_aTranslational Pancreatic Cancer Research : _bFrom Understanding of Mechanisms to Novel Clinical Trials _cedited by Christoph W. Michalski, Jonas Rosendahl, Patrick Michl, Jörg Kleeff
250			_aFirst edition
264		1	_aCham, Switzerland _bSpringer International Publishing _c2020
300			_a1 recurso en línea (XII, 245 páginas) _b18 ilustraciones, 17 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
490	0		_aMolecular and Translational Medicine _x2197-7852
490	0		_aMedicine (SpringerNature-11650)
490	0		_aMedicine (R0) (SpringerNature-43714)
505	0		_aSubtypes of Pancreatic Adenocarcinoma -- Surveillance and Intervention in IPMN -- Novel Biomarkers of Invasive IPMN -- Challenges and Opportunities for Early Pancreatic Cancer Detection: Role for protein biomarkers -- Metabolic Biomarkers of Pancreatic Cancer -- Blood-Based Circulating RNAs as Preventive, Diagnostic, Prognostic and Drugable Biomarkers for Pancreatic Ductal Adenocarcinoma -- Circulating tumor DNA as a novel biomarker for pancreatic cancer -- PDAC Subtypes/Stratification -- Circulating Tumor Cells as Biomarkers in Pancreatic Cancer -- Personalized Models of Human PDAC -- Therapeutic Targeting of Stromal Components -- Epigenetic Targeting -- Targeting Metabolism -- Targeting the Immune System in Pancreatic Cancer -- Phase I Trials in Pancreatic Cancer -- Translational Approaches in Surgical Treatment.
520			_aThis book incorporates a multi-disciplinary approach to present how research results can be translated into clinical trials. The first part begins with a chapter on variants of pancreatic cancer, precursor lesions and groups of people at risk to developing the disease. There is a particular focus on intraductal papillary mucinous neoplasia as a large-scale clinical challenge in pancreatology. The next two parts focus on diagnosis, biomarkers and stratification that emphasize how various approaches to biomarker development are important as both prognostic and predictive tools. The final part consists of personalized treatment approaches that include preclinical models of pancreatic cancer and stromal, epigenetic and metabolism targeting as promising approaches to be translated into early phase clinical trials. Chapters within this part also deal with approaches that are close to being implemented in clinical practice or are already being tested in (early) clinical trials, such as those that targeting the immune systems and strategies to overcome immunotherapy resistance; phase 1 clinical trials and translational approaches in surgical treatment. Written by experts in their fields, Translational Pancreatic Cancer Research provides an outlook towards future directions by integrating information both from basic and clinical research and though demonstrating pathways to better understanding pancreatic cancer and current approaches to translating these into clinical practice.
988			_aSpringer_Medicine_2020
650		7	_2embne _9194247 _aPáncreas _xCáncer
700	1		_aMichalski, Christoph W _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aRosendahl, Jonas _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _1http://viaf.org/viaf/315208968
700	1		_aMichl, Patrick _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _1http://viaf.org/viaf/29154380937130291479
700	1		_aKleeff, Jörg _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030494759
776	0	8	_iPrinted edition: _z9783030494773
776	0	8	_iPrinted edition: _z9783030494780
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-49476-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2020 _dz _ea _zSI